NEW DELHI, December 8, 2015 /PRNewswire/ --
Designing a Novel Platinum Chemotherapeutic (IO-125) for Treatment of Breast Cancer
Invictus Oncology Private Limited, a leader in Supramolecular Therapeutics in Oncology, today announced the presentation of pre-clinical results of their lead molecule, IO-125, at the 2015 San Antonio Breast Cancer Symposium, December 8-12, 2015 (Program Number: P5-03-03 ). IO-125 is a novel platinum-based supramolecular therapeutic and is being developed in triple-negative breast cancer. The results will be shared at the poster presentation (Friday, December 11, scheduled at 5:00 PM CST in the session "Tumor Cell and Molecular Biology: New Drugs and Mechanisms").
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and is associated with a poor prognosis, with a median survival of 13 months. There are limited treatment options for this disease. Recent studies have indicated clinical benefits of platinum agents in TNBC.
Scientists at Invictus Oncology designed IO-125 for superior anti-tumor activity by discovering a novel highly active platinum agent and then utilized their supramolecular platform to enhance its biodistribution to tumors vs. normal tissues. The results show that IO-125 has remarkable and sustained activity in mouse models of TNBC. Based on these observations, IO-125 has entered late stages of pre-clincal development.
A novel supramolecular Platinum therapeutic for treatment of triple negative breast cancer.
Title: Designing a novel Platinum chemotherapeutic (IO-125) for treatment of breast cancer.
Poster Presentation: Friday, December 11, 5:00 - 7:00 PM CST;
Session: Tumor Cell and Molecular Biology: New Drugs and Mechanisms
Program Number: P5-03-03
Presenter: Aniruddha Sengupta, Ph.D., Invictus Oncology, New Delhi, India
The abstract can also be viewed on the SABCS website, http://www.sabcs.org.
About Invictus Oncology Private Limited
Invictus Oncology is a privately held company dedicated towards providing cancer patients a better quality of life by developing new generation cancer drugs with better efficacy and less toxicity. A breakthrough discovery involving the use of supramolecular-based strategies to destroy cancer cells led to the conception of Invictus Oncology. The company was founded in 2011 and is based in New Delhi. With an outstanding team of internationally acclaimed scientists and ground-breaking science, Invictus Oncology is poised to bring the first novel anti-cancer drugs that have been developed in India for global impact.
Invictus Oncology Pvt. Ltd.
SOURCE Invictus Oncology Private Limited